The last 100 years of sepsis

American Journal of Respiratory and Critical Care Medicine

Volumn 173, Issue 3, 2006, Pages 256-263

  Vincent, Jean Louis ^a   Abraham, Edward ^b  

^a ERASME HOSPITAL   (Belgium)

^b NONE

Author keywords

Cytokines; Endotoxin; Epidemiology; Immunomodulation; Septic shock

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANGIOTENSIN; ANTIINFECTIVE AGENT; ANTIOXIDANT; ANTIPYRETIC AGENT; ANTITHROMBIN III; ARACHIDONIC ACID; CORTICOSTEROID; DEXAMETHASONE; DOPAMINE; DROTRECOGIN; HYDROCORTISONE; HYPERTENSIVE FACTOR; IBUPROFEN; ISOPRENALINE; MEPHENTERMINE; METARAMINOL; METHYLENE BLUE; METHYLPREDNISOLONE; N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NORADRENALIN; PENICILLIN G; PHENYLEPHRINE; PROSTAGLANDIN SYNTHASE INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR; UNINDEXED DRUG; VASOACTIVE AGENT; VASOPRESSIN;

ARTIFICIAL VENTILATION; BLEEDING; BLOOD TRANSFUSION; BLOOD VESSEL REACTIVITY; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG MECHANISM; DRUG TOLERABILITY; EPIDEMIOLOGICAL DATA; FEVER; HEMODYNAMIC MONITORING; HUMAN; IMMUNE RESPONSE; INFECTION; INFECTION CONTROL; METABOLIC DISORDER; MORTALITY; MULTIPLE ORGAN FAILURE; MYOCARDIAL DISEASE; NONHUMAN; OXYGENATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEPSIS; SHOCK; SURGICAL TECHNIQUE; TREATMENT PLANNING;

HISTORY, 20TH CENTURY; HUMANS; SEPSIS;

EID: 32144456757     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/rccm.200510-1604OE     Document Type: Review

References (117)

1. Schottmueller H. Wesen und Behandlung der Sepsis. Inn Med 1914;31:257-280.
2. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-3670.
3. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987;i:355-357.
4. Martin C, Boisson C, Haccoun M, Thomachot L, Mege JL. Patterns of cytokine evolution (tumor necrosis factor-alpha and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma. Crit Care Med 1997;25:1771-1773.
5. Sama AE, D'Amore J, Ward MF, Chen G, Wang H. Bench to bedside: HMGB1-a novel proinflammatory cytokine and potential therapeutic target for septic patients in the emergency department. Acad Emerg Med 2004;11:867-873.
6. Bozza FA, Gomes RN, Japiassu AM, Soares M, Castro-Faria-Neto HC, Bozza PT, Bozza MT. Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 2004;22:309-313.
7. Amaral A, Opal SM, Vincent JL. Coagulation in sepsis. Intensive Care Med 2004;30:1032-1040.
8. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
9. Oberholzer A, Oberholzer C, Moldawer LL. Cytokine signaling: regulation of the immune response in normal and critically ill states. Crit Care Med 2000;28:N3-12.
10. Borden CW, Hall WH. Fatal transfusion reactions from massive bacterial contamination of blood. N Engl J Med 1951;245:760-765.
11. Rolleston HD. Discussion on the pathogenic effect of E. coli. BMJ 1911;2:1186.
12. Altschule MD, Freedberg AS, Macmanus MJ. Circulation and respiration during an episode of chill and fever in man. J Clin Invest 1945;24:878-889.
13. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA,Wesley RA, Parrillo JE. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989;321:280-287.
14. Van Deventer SJ, Buller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990;76:2520-2526.
15. Taveira da Silva AM, Kaulbach HC, Chuidian FS, Lambert DR, Suffredini AF, Danner RL. Brief report: shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin. N Engl J Med 1993;328:1457-1460.
16. Levin J, Poore TE, Zauber NP, Oser RS. Detection of endotoxin in the blood of patients with sepsis due to gran-negative bacteria. N Engl J Med 1970;283:1313-1316.
17. Bates DW, Parsonnet J, Ketchum PA, Miller EB, Novitsky TJ, Sands K, Hibberd PL, Graman PS, Lanken PN, Schwartz JS, et al. Limulus amebocyte lysate assay for detection of endotoxin in patients with sepsis syndrome. AMCC Sepsis Project Working Group. Clin Infect Dis 1998;27:582-591.
18. Marshall JC, Walker PM, Foster DM, Harris D, Ribeiro M, Paice J, Romaschin AD, Derzko AN. Measurement of endotoxin activity in critically ill patients using whole blood neutrophil dependent chemiluminescence. Crit Care 2002;6:342-348.
19. Marshall JC, Foster D, Vincent JL, Cook DJ, Cohen J, Dellinger RP, Opal S, Abraham E, Brett SJ, Smith T, et al. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis 2004;190:527-534.
20. Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, Poole-Wilson PA, Coats AJ, Anker SD. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999;353:1838-1842.
21. Parsons PE, Worthen GS, Moore EE, Tate RM, Henson PM. The association of circulating endotoxin with the development of the adult respiratory distress syndrome. Am Rev Respir Dis 1989;140:294-301.
22. Van Deventer SJ, Buller HR, ten Cate JW, Sturk A, Pauw W. Endotoxaemia: an early predictor of septicaemia in febrile patients. Lancet 1988;1:605-608.
23. Wang JE, DahleMK, McDonaldM, Foster SJ,Aasen AO, Thiemermann C. Peptidoglycan and lipoteichoic acid in gram-positive bacterial sepsis: receptors, signal transduction, biological effects, and synergism. Shock 2003;20:402-414.
24. Blain CM, Anderson TO, Pietras RJ, Gunnar RM. Immediate hemodynamic effects of gram-negative vs gram-positive bacteremia in man. Arch Intern Med 1970;126:260-265.
25. Wilson RF, Sarver EJ, Rizzo J. Hemodynamic changes, treatment, and prognosis in clinical shock. Arch Surg 1971;102:21-24.
26. Wiles JB, Cerra FB, Siegel JH, Border JR. The systemic septic response: does the organism matter? Crit Care Med 1980;8:55-60.
27. Moine P, Abraham E. Immunomodulation and sepsis: impact of the pathogen. Shock 2004;22:297-308.
28. Yu SL, Chen HW, Yang PC, Peck K, Tsai MH, Chen JJ, Lin FY. Differential gene expression in gram-negative and gram-positive sepsis. Am J Respir Crit Care Med 2004;169:1135-1143.
29. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA. Sepsis syndrome: a valid clinical entity. Crit Care Med 1989;17:389-393.
30. ACCP-SCCM Consensus Conference. Definitions of sepsis and multiple organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-874.
31. Poeze M, Ramsay G, Gerlach H, Rubulotta F, Levy M. An international sepsis survey: a study of doctors' knowledge and perception about sepsis. Crit Care 2004;8:R409-R413.
32. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-1256.
33. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-1310.
34. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D. Sepsis in European Intensive care Units: Results of the SOAP study. Crit Care Med (In press)
35. Martin GS,Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl JMed 2003;348:1546-1554.
36. Friedman G, Silva E, Vincent JL. Has the mortality of septic shock changed with time? Crit Care Med 1998;26:2078-2086.
37. Alberti C, Brun-Buisson C, Goodman SV, Guidici D, Granton J, Moreno R, Smithies M, Thomas O, Artigas A, Le Gall JR. Influence of systemic inflammatory response syndrome and sepsis on outcome of critically ill infected patients. Am J Respir Crit Care Med 2003;168:77-84.
38. Sands KE, Bates DW, Lanken PN, Graman PS, Hibberd PL, Kahn KL, Parsonnet J, Panzer R, Orav EJ, Snydman DR. Epidemiology of sepsis syndrome in 8 academic medical centers. Academic Medical Center Consortium Sepsis Project Working Group. JAMA 1997;278:234-240.
39. Vincent JL, Bihari D, Suter PM, Bruining HA, White JL, Nicolas-Chanoine MH, Wolff M, Spencer RJ, Hemmer M; Members of the EPIC International Advisory Group. The prevalence of nosocomial infection in intensive care units in Europe: the results of the EPIC study. JAMA 1995;274:639-644.
40. Brun-Buisson C, Meshaka P, Pinton P, Vallet B. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004;30:580-588.
41. Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med 2004;30:589-596.
42. Presterl E, Staudinger T, Pettermann M, Lassnigg A, Burgmann H, Winkler S, Frass M, Graninger W. Cytokine profile and correlation to the APACHE III and MPM II scores in patients with sepsis. Am J Respir Crit Care Med 1997;156:825-832.
43. Luzzani A, Polati E, Dorizzi R, Rungatscher A, Pavan R, Merlini A. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med 2003;31:1737-1741.
44. Dempfle CE, Lorenz S, Smolinski M, Wurst M, West S, Houdijk WP, Quintel M, Borggrefe M. Utility of activated partial thromboplastin time waveform analysis for identification of sepsis and overt disseminated intravascular coagulation in patients admitted to a surgical intensive care unit. Crit Care Med 2004;32:520-524.
45. Opal SM. Concept of PIRO as a new conceptual framework to understand sepsis. Pediatr Crit Care Med 2005;6:S55-S60.
46. Villar J, Maca-Meyer N, Perez-Mendez L, Flores C. Bench-to-bedside review: understanding genetic predisposition to sepsis. Crit Care 2004;8:180-189.
47. Newman SL, Vogler LB, Feigin RD, JohnstonRB Jr. Recurrent septicemia associated with congenital deficiency of C2 and partial deficiency of factor B and the alternative complement pathway. N Engl J Med 1978;299:290-292.
48. Platonov AE, Shipulin GA, Vershinina IV, Dankert J, van de Winkel JG, Kuijper EJ. Association of human Fc gamma RIIa (CD32) polymorphism with susceptibility to and severity of meningococcal disease. Clin Infect Dis 1998;27:746-750.
49. Gibot S, Cariou A, Drouet L, Rossignol M, Ripoll L. Association between a genomic polymorphism within the CD14 locus and septic shock susceptibility and mortality rate. Crit Care Med 2002;30:969-973.
50. Lorenz E, Mira JP, Cornish KL, Arbour NC, Schwartz DA. A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 2000;68:6398-6401.
51. Appoloni O, Dupont E, Andrien M, Duchateau J, Vincent JL. Association of TNF2, a TNFα promoter polymorphism, with plasma TNFα levels and mortality in septic shock. Am J Med 2001;110:486-488.
52. Fang XM, Schroder S, Hoeft A, Stuber F. Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med 1999;27:1330-1334.
53. Stassen NA, Leslie-Norfleet LA, Robertson AM, Eichenberger MR, Polk HC Jr. Interferon-gamma gene polymorphisms and the development of sepsis in patients with trauma. Surgery 2002;132:289-292.
54. Cohen J, Cristofaro P, Carlet J, Opal S. New method of classifying infections in critically ill patients. Crit Care Med 2004;32:1510-1526.
55. Roman-Marchant O, Orellana-Jimenez CE, De Backer D, Melot C, Vincent JL. Septic shock of early or late onset: does it matter? Chest 2004;126:173-178.
56. Volk HD, Reinke P, Krausch D, Zuckermann H, Asadullah K, Müller JM, Döcke WD, Kox WJ. Monocyte deactivation: rationale for a new therapeutic strategy in sepsis. Intensive Care Med 1996;22:S474-S481.
57. Guidet B, Aegerter P, Gauzit R, Meshaka P, Dreyfuss D. Incidence and impact of organ dysfunctions associated with sepsis. Chest 2005;127:942-951.
58. Vincent JL, de Mendonça A, Cantraine F, Moreno R, Takala J, Suter P, Sprung C, Colardyn FC, Blecher S. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicentric, prospective study. Crit Care Med 1998;26:1793-1800.
59. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classi.cation system. Crit Care Med 1985;13:818-829.
60. Le Gall J-R, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 1993;270:2957-2963.
61. Udhoji VN, Wel MH. Hemodynamic and metabolic studies on shock associated with bacteremia. Ann Intern Med 1965;62:966-978.
62. Abraham E, Shoemaker WC, Cheng PH. Cardiorespiratory responses to fluid administration in peritonitis. Crit Care Med 1984;12:664-668.
63. Groeneveld AB, Bronsveld W, Thijs LG. Hemodynamic determinants of mortality in human septic shock. Surgery 1986;99:140-152.
64. Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, Damske BA, Parrillo JE. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 1984;100:483-490.
65. Vincent JL, Gris P, Coffernils M, Leon M, Pinsky MR, Reuse C, Kahn RJ. Myocardial depression characterizes the fatal course of septic shock. Surgery 1992;111:660-667.
66. Duff JH, Groves AC, McLean APH, LaPointe R, MacLean LD. Defective oxygen consumption in septic shock. Surg Gynecol Obstet 1969;128:1051-1060.
67. Fink MP. Bench-to-bedside review: cytopathic hypoxia. Crit Care 2002;6:491-499.
68. Kluger MJ, Ringler DH, Anver MR. Fever and survival. Science 1975;188:166-168.
69. Suzuki S, Hotchkiss JR, Takahashi T, Olson D, Adams AB, Marini JJ. Effect of core body temperature on ventilator-induced lung injury. Crit Care Med 2004;32:144-149.
70. Kregel KC. Heat shock proteins: modifying factors in physiological stress responses and acquired thermotolerance. J Appl Physiol 2002;92:2177-2186.
71. Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, Fulkerson WJ, Wright PE, Christman BW, Dupont WD, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 1997;336:912-918.
72. Weil MH, Shubin H. The "VIP" approach to the bedside management of shock. JAMA 1969;207:337-340.
73. Udhoji VN, Weil MH. Circulatory effects of angiotensin, levarterenol and metaraminol in the treatment of shock. N Engl J Med 1964;270:501-505.
74. MacCannell KL, McNay JL, Meyer MB, Goldberg LI. Dopamine in the treatment of hypotension and shock. N Engl JMed 1966;275:1389-1398.
75. Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D'Alessandro D, Oz MC, Oliver JA. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997;95:1122-1125.
76. Landry DW, Levin HR, Gallant EM, Seo S, D'Alessandro D, Oz MC, Oliver JA. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997;25:1279-1282.
77. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002;96:576-582.
78. Shoemaker WC, Montgomery ES, Kaplan E, Elwyn DH. Physiologic patterns in surviving and nonsurviving shock patients: use of sequential cardiorespiratory variables in defining criteria for therapeutic goals and early warning of death. Arch Surg 1973;106:630-636.
79. Shoemaker WC, Appel PL, Kram HB, Waxman K, Lee TS. Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. Chest 1988;94:1176-1186.
80. Hayes MA, Timmins AC, Yau EH, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994;330:1717-1722.
81. Vincent JL. Hemodynamic support in septic shock: guidelines for the management of severe sepsis and septic shock. International Sepsis Forum. Intensive Care Med 2001;27:S80-S92.
82. Pinsky MR, Vincent JL. Let us use the PAC correctly and only when we need it. Crit Care Med 2005;33:1119-1122.
83. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-1377.
84. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000;356:2139-2143.
85. Spronk PE, Ince C, Gardien MJ,Mathura KR, Oudemans-van Straaten HM, Zandstra DF. Nitroglycerin in septic shock after intravascular volume resuscitation. Lancet 2002;360:1395-1396.
86. Swan HJC, Ganz W, Forrester J, Marcus H, Diamond G, Chonette D. Catheterization of the heart in man using a flow directed balloon tipped catheter. N Engl J Med 1970;283:447-451.
87. Connors AF, Speroff T, Dawson NV, Thomas C, Harrell FE, Wagner D, Desbiens N, Goldman L, Wu AW, Califf RM, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. JAMA 1996;276:889-897.
88. Sakr Y, Creteur J, Vincent JL. An overview of gastric tonometry. Int J Intensive Care 2002;9:129-137.
89. Maciel AT, Creteur J, Vincent JL. Tissue capnometry: does the answer lie under the tongue? Intensive Care Med 2004;30:2157-2165.
90. De Backer D, Creteur J, Preiser JC,Dubois MJ,Vincent JL. Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 2002;166:98-104.
91. Sakr Y, Dubois MJ, De Backer D, Creteur J, Vincent JL. Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med 2004;32:1825-1831.
92. Neviere R, Mathieu D, Chagnon JL, Lebleu N, Millien JP, Wattel F. Skeletal muscle microvascular blood flow and oxygen transport in patients with severe sepsis.Am J Respir Crit Care Med 1996;153:191-195.
93. Piper RD, Pitt-Hyde M, Li F, Sibbald WJ, Potter RF. Microcirculatory changes in rat skeletal muscle in sepsis. Am J Respir Crit Care Med 1996;154:931-937.
94. Broder G, Weil MH. Excess lactate: an index of reversibility of shock in human patients. Science 1964;143:1457-1459.
95. Vincent JL, Dufaye P, Berre J, Leeman M, Degaute JP, Kahn RJ. Serial lactate determinations during circulatory shock. Crit Care Med 1983;11:449-451.
96. De Backer D. Lactic acidosis. Intensive Care Med 2003;29:699-702.
97. Spink WW, Anderson D. Experimental studies on the significance of endotoxin in the pathogenesis of brucellosis. J Clin Invest 1954;33:540-548.
98. Brigham KL, Bowers RE, McKeen CR. Methylprednisolone prevention of increased lung vascular permeability following endotoxemia in sheep. J Clin Invest 1981;67:1103-1110.
99. Motsay GJ,Dietzman RH, Ersek RA, Lillehei RC. Hemodynamic alterations and results of treatment in patients with gram-negative septic shock. Surgery 1970;67:577-583.
100. Kalter ES, Carlson RW, Thijs LG,Weil MH. Effects of methylprednisolone on hemodynamics, arteriovenous oxygen difference, P50, and 2,3 DPG in bacterial shock: a preliminary study. Crit Care Med 1982;10:662-666.
101. Klastersky J, Cappel R, Debusscher L. Effectiveness of betamethasone in management of severe infections. A double-blind study. N Engl J Med 1971;284:1248-1250.
102. Schumer W. Steroids in the treatment of clinical septic shock. Ann Surg 1976;184:333-341.
103. Hoffman SL, Punjabi NH, Kumala S, Moechter MA, Pulungsih SP, Rivai AR, Rockhill RC, Woodward TE, Loedin AA. Reduction in mortality in chloramphenicol treated severe typhoid fever by high dose dexamethasone. N Engl J Med 1984;310:82-88.
104. Bone RC, Fisher CJJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987;317:653-658.
105. Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987;317:659-665.
106. Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MA, Fisher CJ. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995;23:1430-1439.
107. Sibbald WJ, Short A, Cohen MP,Wilson RF. Variations in adrenocortical responsiveness during severe bacterial infections: unrecognized adrenocortical insufficiency in severe bacterial infections. Ann Surg 1977;186:29-33.
108. Minneci PC, Deans KJ, Banks SM, Eichacker PQ, Natanson C. Metaanalysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 2004;141:47-56.
109. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troché G, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-871.
110. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-873.
111. Levin M, Quint PA,Goldstein B, Barton P, Bradley JS, Shemie SD,Yeh T, Kim SS, Cafaro DP, Scannon PJ, et al. Recombinant bactericidal/permeability- increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet 2000;356:961-967.
112. Remick D, Manohar P, Bolgos G, Rodriguez J, Moldawer L, Wollenberg G. Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture. Shock 1995;4:89-95.
113. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, et al. Drotrecogin alfa [activated] for adults with severe sepsis and a low risk of death. N Engl J Med 2005;353:1332-1341.
114. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003;290:238-247.
115. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, et al. Caring for the critically ill patient: high-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286:1869-1878.
116. Taylor FB Jr, Stearns-Kurosawa DJ, Kurosawa S, Ferrell G, Chang AC, Laszik Z, Kosanke S, Peer G, Esmon CT. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 2000;95:1680-1686.
117. Nick JA, Coldren CD, Geraci MW, Poch KR, Fouty BW, O'Brien J, Gruber M, Zarini S, Murphy RC, Kuhn K, et al. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004;104:3878-3885.